Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trialResearch in context

MLA

Joshua J. Todd, et al. “Rycal S48168 (ARM210) for RYR1-Related Myopathies: A Phase One, Open-Label, Dose-Escalation TrialResearch in Context.” EClinicalMedicine, vol. 68, no. 102433-, Feb. 2024. EBSCOhost, https://doi.org/10.1016/j.eclinm.2024.102433.

APA

Joshua J. Todd, Tokunbor A. Lawal, Irene C. Chrismer, Angela Kokkinis, Christopher Grunseich, Minal S. Jain, Melissa R. Waite, Victoria Biancavilla, Shavonne Pocock, Kia Brooks, Christopher J. Mendoza, Gina Norato, Ken Cheung, Willa Riekhof, Pooja Varma, Claudia Colina-Prisco, Magalie Emile-Backer, Katherine G. Meilleur, Andrew R. Marks, … Payam Mohassel. (2024). Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trialResearch in context. EClinicalMedicine, 68(102433-). https://doi.org/10.1016/j.eclinm.2024.102433

Chicago

Joshua J. Todd, Tokunbor A. Lawal, Irene C. Chrismer, Angela Kokkinis, Christopher Grunseich, Minal S. Jain, Melissa R. Waite, et al. 2024. “Rycal S48168 (ARM210) for RYR1-Related Myopathies: A Phase One, Open-Label, Dose-Escalation TrialResearch in Context.” EClinicalMedicine 68 (102433-). doi:10.1016/j.eclinm.2024.102433.